AN2 Therapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2022 to Q3 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: AN2 Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2022 to Q3 2024.
AN2 Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 10.7 %, a 3.2% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q3 2024	10.7	+0.33	+3.2%	Sep 30, 2024
Q2 2024	10.5	+2.06	+24.4%	Jun 30, 2024
Q1 2024	11	+4.88	+80.1%	Mar 31, 2024
Q4 2023	11.2	+6.37	+132%	Dec 31, 2023
Q3 2023	10.3	+4.42	+74.9%	Sep 30, 2023
Q2 2023	8.45			Jun 30, 2023
Q1 2023	6.1			Mar 31, 2023
Q4 2022	4.83			Dec 31, 2022
Q3 2022	5.9			Sep 30, 2022

* An asterisk sign (*) next to the value indicates that the value is likely invalid.